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Introduction
Although gastric cancer has been a leading cause of cancer-
related death in Japan, the number of deaths due to gastric
cancer have been gradually decreasing, and gastric cancer
dropped to the second most common cancer associated
with deaths in 1998. This decrease in deaths from gastric
cancer is considered to be associated with earlier detection
and improved management of the disease, together with the
changing of lifestyle.
Recently, gastric cancer has been detected frequently at an
early stage, and the 5-year survival rate for early gastric cancer
(EGC) is more than 90% in Japan. Several new therapeutic
tools have been developed, and the treatment strategies for
gastric cancer are changing. We report current information on
the pathological characteristics and modern treatments of
EGC in Japan.
Prognostic factors of early gastric cancer
The depth of wall invasion and status of lymph node metastasis
are two major factors predicting the survival of patients with
gastric cancer. The Japanese Gastric Cancer Association defines
EGC as a tumour in which the invasion is restricted to the
mucosa or to the mucosa and submucosa, irrespective of the
lymph node metastasis. Therefore, the most important
prognostic factor of EGC is the presence or absence of lymph
node metastasis.
Endoscopists, radiologists and surgeons often have difficult
in determining the status of lymph node metastasis before or
during surgery, and prophylactic lymph node dissection is
recommended, even if there seems to be no lymph node
metastasis.1,2 The incidence of lymph node metastasis strongly
correlates with the depth of wall invasion: 1% to 3% for tumours
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confined to the mucosa and 11% to 20% for tumours invading
the submucosa.2–5
Several studies clarify that poor outcome after gastrectomy
for EGC is associated with large tumour size, macroscopically
elevated or Borrmann type, histologically well-differentiated
or medullary type, marked lymphatic permeation and high
proliferating activity.6 Occurrence in the young, location in
the upper stomach and histology of mucinous adenocarcinoma
do not correlate with survival of patients with EGC.6
Endoscopy for early gastric cancer
In Japan, endoscopic mucosal resection (EMR) is the standard
treatment modality for patients with small mucosal EGC.7
The grasp and pull technique named “strip biopsy” can be
done using a double-channel endoscope. The cup and suction
technique named “aspiration mucosectomy” is performed
using a cap fitted onto the tip of the endoscope.7,8 Complete-
ness of the endoscopic treatment must be judged by histo-
logical examination of the resected specimen. When there is
submucosal invasion, vessel permeation or a positive resec-
tion margin, gastrectomy with lymph node dissection is
recommended.7
Successful outcome of endoscopic treatment depends on
the selection of patients and practice of accurate procedures.
Many authors studied the pathologic characteristics of node-
negative EGC and proposed clinical criteria for endoscopic
resection. Although the indication for EMR in the early 1990s
included only mucosal cancers measuring less than 1 cm,
the recent indication has extended to mucosal cancers mea-
suring less than 3 cm or tumours invading the superficial
submucosa.3
At the National Cancer Center Hospital in Japan, EMR
is performed on patients with mucosal gastric cancer measur-
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ing less than 3 cm and showing no ulceration or poorly-
differentiated histology.8 Among 445 patients who underwent
EMR, although 25 (5%) experienced perforation, 74 (17%) had
cancer invading the submucosa, and 96 (21%) underwent
successful operative treatments, there were no tumour-related
deaths during a median follow-up period of 38 months.
Surgery for early gastric cancer
Since 1881, Billroth I gastrectomy has been the gold standard
for the treatment of gastric cancer. EGC is safely and success-
fully managed by this conventional gastrectomy because
perigastric lymph nodes are completely harvested. Recently,
several authors have selected patients with EGC in whom
lymph node dissection is unnecessary and introduced limited
resections of the stomach. These procedures include pylorus-
preserving distal gastrectomy, segmental gastrectomy, proxi-
mal gastrectomy and partial gastrectomy or wedge resection.
When compared with the conventional Billroth I
gastrectomy, pylorus-preserving distal gastrectomy and
segmental gastrectomy are characterized by a lower frequency
of dumping syndrome and better quality of patient life.
Proximal gastrectomy reconstructed by jejunal interposition
or gastric tube is a modern surgical procedure for patients with
EGC located in the gastric cardia. Because most patients with
EGC are asymptomatic, limited lymph node dissection and
autonomic nerve preservation contribute to improved
functional results and quality of life after gastrectomy.
Laparoscopy for early gastric cancer
Laparoscopic surgery provides a favourable postoperative
course including less pain, earlier recovery, shorter hospital
stay and earlier return to active daily life. Because of these
benefits, laparoscopic surgery has been introduced as a surgical
option for treatment of gastrointestinal cancers.
In 1993, Ohgami et al9 first developed laparoscopic wedge
resection of the stomach using a lesion-lifting method.
Tumours along the greater curvature or on the anterior wall of
the stomach are good candidates for this method, and the
gastric wall containing mucosal cancer is resected by auto-
suturing under laparoscopy. At the Keio University Hospital,
this technique has been applied to patients with mucosal
gastric cancer measuring less than 2.5 cm. Of 61 patients who
underwent laparoscopic wedge resection, only four (7%) needed
additional surgery, and no patient died of the disease during a
follow-up period ranging from 4 to 65 months.9
In 1992, one of the present co-authors (Kitano) developed
laparoscopy-assisted distal gastrectomy (LADG) for the
management of patients with EGC.10 This technique is an
application of laparoscopy to the Billroth I gastrectomy with
D1 dissection. Therefore, the indication of this procedure
includes EGC invading the mucosa or superficial submucosa
in which metastasis is, if present, restricted to the perigastric
lymph nodes.11 The procedure consists of ligation and division
of the gastric vessels and mobilization of the stomach under
CO2 pneumoperitoneum and resection of the distal two-thirds
of the stomach, followed by a hand-sewn gastroduodenal
anastomosis through a 5-cm-long minilaparotomy incision.
When compared with conventional open gastrectomy,
laparoscopic gastrectomy has several advantages including
less pain, less inflammatory response, faster recovery of gut
function, shorter hospital stay, lower hospital charges and
better quality of life.12,13 Recently, some Japanese surgeons
have demonstrated that gastrectomy with D2 dissection for
advanced gastric cancer is feasible using laparoscopic surgery14
and hand-assisted laparoscopic surgery (HALS), although their
long-term results are not known.
Japanese guidelines for gastric cancer
In March 2001, the Japanese Gastric Cancer Association
proposed clinical guidelines for the treatment of patients with
gastric cancer. Treatment strategies are determined in detail
based on the depth of wall invasion and status of lymph node
metastasis. When lymph node metastasis is not suspected,
EGC can be managed by both endoscopic and surgical
treatments. EMR can be performed for well-differentiated
tumours confined to the mucosa, without ulceration and
measuring less than 2 cm. Distal gastrectomy (D1 + No. 7) can
be performed for other tumours confined to the mucosa and
for well-differentiated tumours invading the submucosa
measuring less than 1.5 cm. Finally, distal gastrectomy (D1 +
No.7, 8a, 9) can be used for the remaining tumours invading
the submucosa.
When lymph node metastasis is suspected, EGC must be
treated surgically with distal gastrectomy (D1 + No.7, 8a, 9) for
tumours measuring less than 2 cm, whereas distal gastrectomy
(D2) is reserved for tumours measuring more than 2 cm. Thus,
about half of the patients with mucosal cancer are candidates
for endoscopic treatment, while the other half are candidates
for distal gastrectomy (D1). Most patients with tumours
invading the submucosa are candidates for distal gastrectomy
(D2).
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Conclusion
Although many treatment modalities for EGC demonstrate
successful results, further improvement is achieved by earlier
detection of EGC and treatment with more advanced instru-
ments and techniques. Continuing follow-up, functional
analysis and psychosocial evaluation by randomized controlled
trials15 will refine the indications and selection criteria for
several EGC treatment modalities. Endoscopic or laparoscopic
treatment is considered to be a promising approach for patients
with EGC.
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